Foundation Medicine
Foundation Medicine, Sumitomo Pharma to Develop CDx for Acute Leukemia Treatment
The companies will use the FoundationOne Heme platform to identify patients with acute leukemia who have a KMT2A rearrangement or NPM1 mutations.
Real-World Data Analysis Confirms Pan-Cancer Predictiveness of Foundation Medicine TMB Caller
Premium
The company worked with clinical investigators to analyze outcomes data across more than 8,000 treated individuals, reconfirming the validity of its FDA-approved TMB indication.
Foundation Medicine, Fulgent Genetics Partner to Launch Germline Testing in US
The Foundation Medicine next-generation sequencing-based panels use Fulgent's technology platform and will analyze genes associated with hereditary cancers.
Foundation Medicine Assay Nabs FDA Approval as CDx for Ojemda in Pediatric Patients
The FoundationOne test can be used to identify patients with relapsed or refractory BRAF-altered pediatric low-grade glioma who may be eligible for therapeutic options.
In Brief This Week: Myriad Genetics, Europa Biosite, Mount Sinai, DeepUll, Thermo Fisher, More
News items for the weeks of Nov. 25 and Dec. 2, 2024.
Jul 24, 2024